Incannex Healthcare (IXHL) Expected to Announce Quarterly Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) will likely be releasing its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect Incannex Healthcare to post earnings of ($0.02) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, February 13, 2026 at 12:30 PM ET.

Incannex Healthcare (NASDAQ:IXHL) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.37. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.20 million.

Incannex Healthcare Stock Performance

Shares of IXHL opened at $0.25 on Friday. The firm’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.46. Incannex Healthcare has a fifty-two week low of $0.08 and a fifty-two week high of $2.24. The stock has a market cap of $86.56 million, a PE ratio of -0.42 and a beta of 7.46.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Incannex Healthcare in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Incannex Healthcare

A hedge fund recently bought a new stake in Incannex Healthcare stock. Virtu Financial LLC acquired a new position in Incannex Healthcare Inc. (NASDAQ:IXHL) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 402,443 shares of the company’s stock, valued at approximately $187,000. Virtu Financial LLC owned 0.12% of Incannex Healthcare as of its most recent SEC filing. 0.43% of the stock is owned by institutional investors.

About Incannex Healthcare

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.